Specialty hub

Neurology (CNS) and Pain

Containing dedicated Learning Zones, guidelines, trials and news for related conditions in Neurology (CNS) and Pain.

Read time: 5 mins

Last updated: 9th Mar 2023

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Neurology is the branch of medicine that deals with conditions and diseases involving the central nervous system (brain and spinal cord) and the peripheral nervous systems (autonomic and somatic), including their coverings, blood vessels, and all effector tissue such as muscle.

Learning Zones

Learning Zone Homepage

Multiple Sclerosis Resources

100 mins

Myocardium Cardiac muscle fibers banner image

Learning Zone Homepage

Pompe Disease: Key findings from WMS 2022

80 mins

Learning Zone Homepage

Biomarker innovation in Alzheimer’s disease Learning Zone

60 mins

Learning Zone Homepage

Anticoagulation Therapy for Stroke Prevention

300 mins

Learning Zone Homepage

Multiple Sclerosis (MS) Learning Zone

160 mins

Learning Zone Homepage

One Neuroscience and Pain Learning Zone

830 mins

Pompe Disease: ACCME accredited roundtable video

0.75 CME credits, expert opinion, and discussion on key developments in Pompe disease from the 2022 World Muscle Society Congress which was held in Halifax, Canada 11–15 October.

Learn more

Key developments in amyloidosis from ISA 2022

Read about the latest research on and management of amyloidosis with highlights from the 18th International Symposium on Amyloidosis (ISA) 2022 from Heidelberg, Germany, and an interview with AL amyloidosis expert Professor Giovanni Palladini.

Read now

Neurology encompasses over 5000 neurological diseases and relies on insights from fields such as neuroscience. This medical speciality deals with dementia including Alzheimer’s disease, Parkinson’s disease, neuromuscular disorders including spinal muscular atrophy and pain management as a sub-speciality.

Diseases in this section

Attention Deficit Hyperactivity Disorder (ADHD)

Containing relevant Learning Zones, guidelines, trials and news.

Dementia

Containing relevant Learning Zones, guidelines, trials and news.

Depression

Containing relevant Learning Zones, guidelines, trials and news.

Epilepsy

Containing relevant Learning Zones, guidelines, trials and news.

Herpes Zoster

Containing relevant Learning Zones, guidelines, trials and news.

Neuromuscular Disorders

Containing relevant Learning Zones, guidelines, trials and news.

Pain

Containing relevant Learning Zones, guidelines, trials and news.

Parkinson's Disease

Containing relevant Learning Zones, guidelines, trials and news.

Opioid prescribing for chronic noncancer pain in general practice

How should general practitioners assess patient pain and consider treatment? Read our original article investigating current advice and good clinical practice.

Learn more

Related news and insights

Drug news

New four-year data for Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy .- Genentech/Roche

Genentech, a member of the Roche Group announced new long-term data for Evrysdi (risdiplam) in a broad range of people aged 2-25 years with spinal muscular atrophy (SMA) from the pivotal SUNFISH study.

3 mins

Drug news

Zolgensma long-term data demonstrates sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset.- Novartis

Novartis presented new data which underscore the transformational and sustained benefit of Zolgensma (onasemnogene abeparvovec), an essential one-time gene therapy for the treatment of spinal muscular atrophy (SMA).

6 min

Drug news

FDA approves Dayblue to treat Rett Syndrome.- Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc. announced that the FDA has approved Dayblue (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. Dayblue is the first and only drug approved for the treatment of Rett syndrome.

1 min

See all news

Related Drugs

FDA Hero Banner - Multi-coloured pills and tablets

Paroxetine PAROXETINE HYDROCHLORIDE HEMIHYDRATE 40 mg/1 REMEDYREPACK INC.

2 mins

PAXIL PAROXETINE HYDROCHLORIDE 10 mg/5mL Apotex Corp

2 mins

Bupivacaine Hydrochloride BUPIVACAINE HYDROCHLORIDE 5 mg/mL Eugia US LLC

6 mins

LIDOCAINE HYDROCHLORIDE LIDOCAINE HYDROCHLORIDE 20 mg/mL General Injectables & Vaccines, Inc.

4 mins

Duloxetine DULOXETINE HYDROCHLORIDE 60 mg/1 Inventia Healthcare Private Limited

6 mins

Venlafaxine VENLAFAXINE HYDROCHLORIDE 25 mg/1 Alembic Pharmaceuticals Limited

3 mins

Baclofen BACLOFEN 5 mg/1 Amneal Pharmaceuticals of New York LLC

1 mins

Duloxetine DULOXETINE HYDROCHLORIDE 20 mg/1 Quallent Pharmaceuticals Health, LLC

6 mins

Doxepin Hydrochloride DOXEPIN HYDROCHLORIDE 10 mg/1 First Nation Group, LLC

1 mins

Eletriptan hydrobromide ELETRIPTAN HYDROBROMIDE 40 mg/1 Quality Care Products, LLC

1 mins

Oxcarbazepine OXCARBAZEPINE 150 mg/1 Cardinal Health 107, LLC

5 mins

Oxcarbazepine OXCARBAZEPINE 300 mg/1 Cardinal Health 107, LLC

5 mins

Lidocaine Hydrochloride LIDOCAINE HYDROCHLORIDE 20 mg/mL General Injectables & Vaccines, Inc

2 mins

VENLAFAXINE VENLAFAXINE HYDROCHLORIDE 37.5 mg/1 Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.

4 mins

SERTRALINE HYDROCHLORIDE SERTRALINE HYDROCHLORIDE 25 mg/1 ACI Healthcare USA, Inc.

5 mins

Related Journals

Journal

Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression

1 mins

Journal

Research Progress on Classical Traditional Chinese Medicine Jieyu Pills in the Treatment of Depression

1 mins

Journal

Vagus Nerve Stimulation For Treatment Resistant Depression: Case Series Of Six Patients - Retrospective Efficacy And Safety Observation After One Year Follow Up

1 mins

Journal

Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study

1 mins

Journal

Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response

1 mins

Journal

Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment-resistant major depressive disorder

1 mins

Journal

Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial

1 mins

Journal

Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression

1 mins

Journal

At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study

1 mins

Journal

Genetic comorbidity between major depression and cardio-metabolic traits, stratified by age at onset of major depression

1 mins

Related Guidelines

Guideline

Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement

These recommendations were designed to ensure safety for patients with major depressive disorder (MDD) and to aid monitoring and management of adverse effects during treatment with approved antidepressant medications. The recommendations aim to inform prescribers about both the risks associated with these treatments and approaches for mitigating such risks.

1 mins

Guideline

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use.

1 min

Guideline

Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental

Background: Clear guidance for successive antidepressant pharmacological treatments for non-responders in major depression is not well established.

1 min

See all guidelines